SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Calcium Channels & Calcium Channel Antagonists
Ann Neurol 21:317-330, Greenberg,D.A., 1987
Association of Coffee Consumption and Prediagnostic Caffeine Metabolites with Incident Parkinson Disease in a Population-Based Cohort
Neurol 102:e209201, Zhao,Y.,et al, 2024
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: No
Stroke 40:3161-3162, 3163, Strauss,M. &Hall,A., 2009
Angiotensin Receptor Blockers Should Be Regarded as First-Line Drugs for Stroke Prevention in Both Primary and Secondary Prevention Settings: Yes
Stroke 40:3159-3160, 3163, Hackam,D., 2009
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Therapeutic Hypothermia for Global and Focal Ischemic Brain Injury-A Cool Way to Improve Neurologic Outcomes
Neurologist 13:331-342, Hoesch,R.E. &Geocadin,R., 2007
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Piracetam for Acute Ischemic Stroke
Stroke 37:2191-2192, Ricci,S.,et al, 2006
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Calcium Antagnosits in Aneurysmal Subarachnoid Hemorrhage
Stroke 36:1816-1817, Rinkel,G.J.E.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005
Magnesium for Acute Stroke (Intravenous Magnesium Efficacy in Stroke Trial):Randomised Controlled Trial
Lancet 363:439-445,414, Goldstein,L.B., 2004
Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
Alcohol Consumption and Risk of Stroke
JAMA 289:579-588, Reynolds,K.,et al, 2003
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Alcohol Consumption and Risk of Ischemic Stroke
Stroke 33:907-912,890, Djousse,L,et al, 2002
Prognostic Significance of Uric Acid Serum Concentration in Patients with Acute Ischemic Stroke
Stroke 33:1048-1052, Chamorro,A.,et al, 2002
Calcium Antagonists for Ischemic Stroke
Stroke 32:570-576, Horn,J. &Limburg,M., 2001
Human Albumin Therapy of Acute Ischemic Stroke
Stroke 32:553-560, Belayev,L.,et al, 2001
Cooling for Acute Ischemic Brain Damage (COOL AID)
Stroke 32:1847-1854, Krieger,D.W.,et al, 2001
New Imaging Strategies for Patient Selection for Thrombolytic and Neuroprotective Therapies
Neurol 57:S48-S52, Warach,S., 2001
Aptiganel Hydrochloride in Acute Ischemic Stroke
JAMA 286:2673-2682,2718, Albers,G.W.,et al, 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Stroke 30:1969-1973, Vaughan,C.J.&Delanty,N., 1999
Combating Hyperthermia in Acute Stroke, A Significant Clinical Concern
Stroke 29:529-534, Ginsberg,M.D.&Busto,R., 1998
Duration of Neuroprotective Treatment for Ischemic Stroke
Stroke 29:535-542, Dyker,A.G.&Lees,K.R., 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997
Lubeluzole Treatment of Acute Ischemic Stroke
Stroke 28:2338-2346, Grotta,J., 1997
Treatment of Acute Ischemic Stroke with Piracetam
Stroke 28:2347-2352, DeDeyn,P.P.,et al, 1997
Lubeluzole in Acute Ischemic Stroke:A Double-Blind Placebo-Controlled Phase II Trial
Stroke 27:76-81, Diener,H.C.,et al, 1996
Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:29-361996., , 1996
Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Patients Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:37-451996., , 1996
The Relation Between Fish Consump & Stroke Incidence, NHANES I Epidemiol Study
Arch Int Med 156:537-542, Gillum,R.F.,et al, 1996
A 60-Year-Old Man with Parkinson's Disease
JAMA 275:716-722, Olanow,C.W., 1996
Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996